Major Depressive Disorder and Diabetes: Does Serotonin Bridge the Gap?

Author(s): Nicole E. De Long, Rebecca A. Stepita, Valerie H. Taylor, Alison C. Holloway.

Journal Name: Current Diabetes Reviews

Volume 11 , Issue 2 , 2015

Become EABM
Become Reviewer

Abstract:

Major depressive disorder (MDD) is one of the most common psychiatric illnesses worldwide, with reported prevalence rates ranging between 10% and 19%. Pharmacotherapy is a first-line option for the management of MDD and, as a result, the use of antidepressants has increased 4 fold in the last 20 years. Serotonin is the most commonly dysregulated neurotransmitter in the etiology of MDD and this system is the primary focus of most medications used in the treatment of illness. Although antidepressant use in adults increases the risk of developing new onset type 2 diabetes, the mechanisms underlying this association are poorly defined. This review will focus on 1) the evidence from human and animal studies suggesting a link between the use of antidepressants that target serotonin signaling (i.e., SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), and noradrenergic and specific serotonergic antidepressants (NaSSAs)) and increased risk of diabetes, and 2) the mechanisms by which alterations in serotonin signalling by antidepressants can affect glucose homeostasis.

Keywords: Antidepressants, insulin, noradrenergic and specific serotonergic antidepressants selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, type 2 diabetes.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 2
Year: 2015
Page: [71 - 78]
Pages: 8
DOI: 10.2174/1573399811666150223123053
Price: $65

Article Metrics

PDF: 45
HTML: 2